“A prospective, randomized and double blind once-monthly oral Ibandronate and Risedronate in post-menopausal osteoporosis leprosy patients” (2017) International Journal of Biomedical and Advance Research, 8(11), pp. 407–415. doi:10.7439/ijbar.v8i11.4474.